Avichai Shimoni, Irit Avivi, Jacob M. Rowe, Moshe Yeshurun, Itai Levi, Reuven Or, Paulina Patachenko, Abraham Avigdor, Tzila Zwas and Arnon Nagler A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma Cancer 118
Version of Record online: 17 JAN 2012 | DOI: 10.1002/cncr.27418
Ibritumomab tiuxetan (Zevalin) combined with BEAM high-dose chemotherapy is safe and possibly more effective than BEAM alone as a conditioning regimen for autologous stem cell transplantation in the era of rituximab-containing chemotherapy regimens.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field